Newly diagnosed acute promyelocytic leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute promyelocytic leukemia (APL) is a high-risk hematologic emergency.
• Early mortality in APL necessitates prompt treatment initiation.
• Cytologic criteria guide the immediate commencement of all-trans retinoic acid (ATRA).

Purpose of the Study:

• To outline recommended treatment strategies for newly diagnosed acute promyelocytic leukemia.
• To detail induction, consolidation, and maintenance therapy protocols.
• To emphasize management of coagulopathy and differentiation syndrome.

Main Methods:

• Induction therapy with ATRA plus anthracycline-based chemotherapy.
• Alternative induction with arsenic trioxide plus ATRA for specific patients.
• Risk-stratified consolidation chemotherapy with ATRA for patients achieving complete remission (CR).

Main Results:

• Intensive consolidation therapy may allow omission of maintenance treatment.
• Intermittent ATRA is suggested for maintenance if required.
• Reduced ATRA dosage for pediatric patients and reduced intensity chemotherapy for elderly patients are recommended.

Conclusions:

• Careful management of coagulopathy and differentiation syndrome is vital for survival.
• Molecular monitoring using PCR for PML/RARA fusion gene is essential for follow-up.
• Tailored treatment approaches based on age and risk group improve outcomes in APL.